Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers
Go back to Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers| GALMED PHARMACEUTIC (NASDAQ: GLMD) | Delayed: 0.61 -0.01 (1.61%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.62 | 52 Week High | $9.70 | |||
| Open | $0.59 | 52 Week Low | $2.78 | |||
| Day High | $0.63 | P/E | N/A | |||
| Day Low | $0.58 | EPS | $0.00 | |||
| Volume | 195,796 | |||||
